Johnson & Johnson Stock Sao Paulo

Equities

JNJB34

BRJNJBBDR002

Pharmaceuticals

Delayed Sao Paulo 10:04:39 2024-06-12 am EDT 5-day change 1st Jan Change
52.49 BRL +2.99% Intraday chart for Johnson & Johnson +1.59% +4.15%
Sales 2024 * 88.79B 480B Sales 2025 * 92.1B 498B Capitalization 353B 1,910B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.98 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.83 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 131,900
Yield 2024 *
3.29%
Yield 2025 *
3.43%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.99%
1 week+1.59%
Current month+2.12%
1 month+1.49%
3 months-2.81%
6 months+2.62%
Current year+4.15%
More quotes
1 week
50.80
Extreme 50.8
52.80
1 month
49.65
Extreme 49.65
52.89
Current year
49.65
Extreme 49.65
54.37
1 year
47.60
Extreme 47.6
58.25
3 years
47.60
Extreme 47.6
66.01
5 years
32.10
Extreme 32.0967
66.01
10 years
15.13
Extreme 15.1327
66.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-06-12 52.49 +2.99% 396
24-06-11 52.44 -0.23% 3,036
24-06-10 52.56 +0.50% 2,896
24-06-07 52.3 +1.63% 2,874
24-06-06 51.46 -0.41% 4,645

Delayed Quote Sao Paulo, June 12, 2024 at 10:04 am EDT

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
146.8 USD
Average target price
171.7 USD
Spread / Average Target
+17.01%
Consensus